Highlights of this expansion include the addition of R&D and commercial scale fluid bed technology, OptiMelt™ hot melt extrusion and elevated cGMP compliance for handling of OEB class 3 customer products.
With these expanded capabilities, Catalent Schorndorf is now even better positioned to deliver customers with solutions for their most difficult bioavailability, controlled release or targeted delivery profile challenges.
“This expansion follows recent investments in OSDrC® OPTIDOSETM optimized controlled release dose delivery technology at our Winchester, Kentucky site in the US, and Lyopan® fast-dissolve lyophilized tablet technology, representing Catalent's commitment to continue innovating and furthering it's position as the industry's leading global partner in oral drug delivery technologies,” stated Dr. Ian Muir, President of Catalent's Modified Release Technologies business.
To learn more about Catalent's Modified Release technologies, go here.
With these expanded capabilities, Catalent Schorndorf is now even better positioned to deliver customers with solutions for their most difficult bioavailability, controlled release or targeted delivery profile challenges.
“This expansion follows recent investments in OSDrC® OPTIDOSETM optimized controlled release dose delivery technology at our Winchester, Kentucky site in the US, and Lyopan® fast-dissolve lyophilized tablet technology, representing Catalent's commitment to continue innovating and furthering it's position as the industry's leading global partner in oral drug delivery technologies,” stated Dr. Ian Muir, President of Catalent's Modified Release Technologies business.
To learn more about Catalent's Modified Release technologies, go here.
Companies in this press-release
